Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)(COMPLETED)
This study has been completed.
Information provided by:
First received: May 2, 2002
Last updated: March 15, 2011
Last verified: March 2011
A clinical study to determine the efficacy and safety of an Treatment of MK0869 in the treatment of depression.
Major Depressive Disorder
Drug: MK0869, aprepitant
Drug: Comparator: placebo
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Multicenter, Placebo-and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Merck:
Primary Outcome Measures:
- HAMD-17 total score at week 8. Tolerability.
Secondary Outcome Measures:
- CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8
|Study Start Date:||November 2001|
|Study Completion Date:||December 2003|
The duration of treatment is 8 weeks.
Contacts and Locations